Larry D. Lynd
Scientist, PHD, BSP
Dr. Larry Lynd is a Professor and the Dean pro tem in the University of British Columbia (UBC) Faculty of Pharmaceutical Sciences and is the Director of the Collaboration for Outcomes Research and Evaluation.
- Health services research
- Risk-benefit analysis
- Health economics
- Outcomes research
- Longitudinal analysis
- Population health
Formerly, he was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes of Health Research (CIHR) New Investigator.
Dr. Lynd has more than 200 peer-reviewed publications, book chapters, and research abstracts. Recently, he was appointed as the Chair of the Health Canada Special Advisory Committee on Nonprescription Drugs, and to the Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, and he sits as the economics expert on the B.C. Ministry of Health Services Expensive Drugs for Rare Diseases Committee. His primary research interests are in the areas of risk-benefit analysis, pharmacoepidemiology, health economics, and policymaking for drugs for rare diseases. He is the principal investigator on the CIHR New Emerging Team for Rare Diseases, focused on policy and decision-making for orphan drugs. Projects include Million Dollar Meds.
- Dean pro tem, Faculty of Pharmaceutical Sciences, UBC
- Professor, Faculty of Pharmaceutical Sciences, UBC
- Director, Collaboration for Outcomes Research and Evaluation
- Research Scientist, Centre for Clinical Epidemiology and Evaluation, VCHRI
- Use of inhaled steroids linked to reduced lung cancer risk in COPD patients (The Province, May 2019)
- Top Canadian researchers at the helm of pioneering Canadian Proactive Cohort Study for People Living with MS (CanProCo) (Cision Newswire, December 2018)
- New UBC journalism project aims to raise awareness about rare diseases (Global News, February 2016)